Consensus Update for Systemic Treatment of Atopic DermatitisConsensus Update for Systemic Treatment of Atopic Dermatitis
- Other Titles
- Consensus Update for Systemic Treatment of Atopic Dermatitis
- Authors
- Lee, Ji Hyun; Kim, Jung Eun; Park, Gyeong-Hun; Bae, Jung Min; Byun, Ji Yeon; Shin, Min Kyung; Han, Tae Young; Hong, Seung Phil; Jang, Yong Hyun; Kim, Hye One; Na, Chan Ho; Lew, Bark-Lynn; Ahn, JiYoung; Park, Chang Ook; Seo, Young-Joon; Lee, Yang Won; Son, Sang Wook; Choi, Eung Ho; Park, Young Lip; Roh, Joo Young
- Issue Date
- Dec-2021
- Publisher
- 대한피부과학회
- Keywords
- Atopic dermatitis; Consensus; Republic of Korea; Systemic treatment; Therapeu-tics
- Citation
- Annals of Dermatology, v.33, no.6, pp 497 - 514
- Pages
- 18
- Journal Title
- Annals of Dermatology
- Volume
- 33
- Number
- 6
- Start Page
- 497
- End Page
- 514
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/20126
- DOI
- 10.5021/ad.2021.33.6.497
- ISSN
- 1013-9087
2005-3894
- Abstract
- Background: In 2015, the Korean Atopic Dermatitis Association (KADA) working group published consensus guidelines for treating atopic dermatitis (AD). Objective: We aimed to provide updated consensus recommendations for systemic treatment of AD in South Korea based on recent evidence and experience. Methods: We compiled a database of references from relevant systematic reviews and guidelines on the systemic management of AD. Evidence for each statement was graded and classified based on thestrength of the recommendation. Forty-two council members from the KADA participated in three rounds of voting to establish a consensus on expert recom-mendations. Results: We do not recommend long-term treatment with systemic steroids forpatients with moderate-to-severe AD due to the risk of adverse effects. We recommend treatment with cyclosporine or dupilumab and selective treatment with methotrexate or azathioprine for patients with moderate-to-severe AD. We suggest treatment with antihistamines as an option for alleviating clinical symptoms of AD. We recommend selective treatment with narrowband ultraviolet B for patients with chronic moderate-to-severe AD. We do not rec-ommend treatment with oral antibiotics for patients with moderate-to-severe AD but who have no signs of infection. We did not reach a consensus on recommendations for treat-ment with allergen-specific immunotherapy, probiotics, evening primrose oil, orvitamin D for patients with moderate-to-severe AD. We also recommend educational interventions and counselling for patients with AD and caregivers to improve the treatment success rate. Conclusion: We look forward to implementing a new and updated consensus of systemic therapy in controlling patients with moderate-to-severe AD.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Dermatology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.